君百延(08372.HK)斥25萬美元認購Techmetics股份 並設合營拓自主移動機器人解決方案
君百延(08372.HK)公佈,於11月24日與Techmetics訂立投資協議,Techmetics將向公司配發及發行認購股份,相當於其經擴大後已發行股本的0.95%,總認購價爲25萬美元,摺合約195萬港元。
君百延並將透過附屬,與公司主席、行政總裁兼執行董事黃碧君及Techmetics成立合營企業,合營公司的初始註冊股本爲50萬美元,將由君百延、黃碧君及Techmetics分別以現金出資20%、40%及40%。
合營公司將主要從事於相關司法權區爲醫療保健行業提供自主移動機器人解決方案;物色原設備生產商;及研發工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.